Menu
Not yet recruiting NCT07090603

The Effects of Age on Muscle Endurance During Resistance Exercise With and Without Blood Flow Restriction

No phase Interventional Ageing Muscle Fatigue Caused by Repetitive Muscle Exercise

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Knee extension exercise.
Who it may be relevant to
Registry conditions: Ageing, Muscle Fatigue Caused by Repetitive Muscle Exercise. Basic parameters: from 19 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Age-Related Differences in Skeletal Muscle Endurance Responses to Various Relative Loads of Dynamic Resistance Exercise With and Without Peripheral Blood Flow Occlusion

Overview

The purpose of this study is to learn how aging affects muscle endurance during resistance exercise, and how oxygen delivery to the muscles plays a role in these changes. To answer this question, we are comparing how many repetitions of a leg exercise (knee extensions) younger and older adults can do at different exercise intensities. We will also look at how the muscles use oxygen during these exercises. Participants will take part in 12 different exercise sessions. In each session, they will perform as many knee extensions as possible using different amounts of weight-consisting of 20%, 30%, 40%, 50%, 60% and 70% of the maximum weight they can lift one time. Each weight will be tested both with and without a cuff on the leg that temporarily reduces blood flow to the muscle.

Interventions

  • Other Knee extension exercise
    Maximum repetitions of knee extension exercise at 20%, 30%, 40%, 50%, 60% and 70% of participants one rep max with and without blood flow occlusion

Primary outcome measures

  • Maximum repetitions performed during knee extension exercise [Time frame: From enrollment to the end of the final study visit (~4 weeks)]
Secondary outcome measures (1)
  • Local muscle tissue oxygenation during knee extension exercise [Time frame: From enrollment to the end of the final study visit (~ 4 weeks)]

Eligibility criteria

Inclusion criteria

  • Able to understand and communicate in English
  • 19-35 years of age
  • 65 years of age or older
  • All "No" answers on the CSEP Get Active questionnaire or doctors' approval to participate

Exclusion criteria

  • BMI lower than 18 or greater than 32
  • Current use of cigarettes or other nicotine devices
  • Any major uncontrolled cardiovascular, muscular, metabolic, and/or neurological disorders
  • Any medical condition impacting the ability to participate in maximal exercise
  • Type one or type two diabetes
  • Diagnosis of cancer or undergoing cancer treatment in the past 12 months
  • Taking blood-thinning medication or the presence of a bleeding disorder
  • Drug therapy with any drugs that alter skeletal muscle metabolism (i.e., Metformin, Benzodiazepines)
  • Lowest calculated exercise testing load is less than the lightest weight able to be provided by the lab gymnasium equipment
  • In the past six months, completing more than 300 minutes of moderate physical activity or 150 minutes of vigorous physical activity per week
  • In the past six months, completing less than 150 minutes of moderate physical activity or 75 minutes of vigorous physical activity

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

Canada · 1 center
  • Chan Gunn Pavilion — Vancouver

Identifiers

NCT: NCT07090603 · H25-01532

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗